HIGHLIGHTS
- who: Michael Benzaquen and colleagues from the Department of Dermatology, Inselspital-Bern University Hospital, University of Bern, Bern, Switzerland have published the paper: Long-Term Dose Optimization of Adalimumab via Dose Spacing in Patients with Psoriasis, in the Journal: Bioengineering 2022, 387 of /2022/
- what: The aim of the study was to evaluate the follow-up of psoriatic patients after adalimumab DS regarding the clinical course and determination of circulating adalimumab TNFα levels and anti-adalimumab antibodies. The study was approved by the ethical committee of the Canton of Bern (KEK-2019-00313) and conducted . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.